An Open-Label Trial of Pregabalin in Patients With Fibromyalgia
The main purpose of this protocol is to evaluate the long-term safety of pregabalin in patients who participated in the previous fibromyalgia Study A0081056 and who wish to receive open-label pregabalin therapy.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Long-Term, Open-Label, Safety Trial of Pregabalin in Patients With Fibromyalgia|
- Main outcome of the study is long-term safety of pregabalin in patients with fibromyalgia. This is a 1 year open-label extension of the preceding double-blind randomized fibromyalgia protocol A0081056.
- There are no secondary outcome measures [ Designated as safety issue: No ]
|Study Start Date:||January 2005|
|Estimated Study Completion Date:||June 2006|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00151528
Show 94 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|